Impact of intracoronary reteplase during primary percutaneous coronary intervention on infarct size in large anterior myocardial infarction: rationale and design of the RECOVER II trial

Dong Huang, Yuanji Ma, Hongxian Wu, Xin Zhong, Wei Gao, Jun Zhou, Juying Qian, Junbo Ge, Dong Huang, Yuanji Ma, Hongxian Wu, Xin Zhong, Wei Gao, Jun Zhou, Juying Qian, Junbo Ge

Abstract

Background: Thrombus embolization and microvascular obstruction during percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) is commonly detected, which causes inadequate myocardial perfusion and elevated infarct size. An approach with low-dose intracoronary fibrinolytic treatment for reducing distal embolization and improving myocardial reperfusion in high-risk STEMI cases remains controversial.

Methods: The RECOVER II study represents a multicenter, randomized, double-blind, parallel-group trial assessing low-dose adjunctive intracoronary reteplase during primary PCI in individuals with large anterior myocardial infarction and thrombus determined by angiography. The trial will enroll 306 cases who present within 12 h following STEMI for proximal or mid left anterior descending artery occlusion undergoing primary PCI. Cases will be randomized to receive a bolus intracoronary reteplase at 9 mg or 18 mg vs. placebo. The drug will be delivered over 2 minutes proximal to culprit lesions with an intracoronary catheter early after wire-crossing and before thrombus aspiration or balloon dilation.

Results: The primary outcome will be infarct size assessed by late gadolinium-enhanced magnetic resonance imaging (MRI) (% of left ventricular mass) on day 7 after enrollment. Secondary outcomes will include the amount of microvascular obstruction and myocardial salvage index examined via MRI on day 7, angiographic measures of reperfusion [Thrombolysis in Myocardial Infarction (TIMI) coronary flow grade, TIMI frames count and myocardial blush grade], incidence of complete ST-segment resolution at 2 hours after reperfusion, area under the curve for troponin T, and rates of major adverse cardiovascular events at 30 days.

Conclusions: RECOVER II will determine whether the addition of low-dose intracoronary reteplase early after wire-crossing as an adjunct to reperfusion treatment reduces infarct size in individuals with large anterior myocardial infarction.

Trial registration: ClinicalTrials.gov Identifier: NCT04571580.

Keywords: Myocardial infarction; infarct size; percutaneous coronary intervention (PCI); reteplase.

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://cdt.amegroups.com/article/view/10.21037/cdt-21-756/coif). The authors have no conflicts of interest to declare.

2022 Cardiovascular Diagnosis and Therapy. All rights reserved.

Figures

Figure 1
Figure 1
Flowchart of RECOVER II. PCI, percutaneous coronary intervention; MRI, magnetic resonance imaging.

Source: PubMed

3
Sottoscrivi